You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product Overview

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Drug-disease modelling: BPH Webinar 25th September 2019

ELITE Webcast

DRUG-DISEASE MODELLING:

The impact of early vs delayed initiation of combination therapy for BPH medical management

Watch expert discussion on clinical management now.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Combodart is a registered trademark of the GlaxoSmithKline group of companies